new report $1.47 target...breaking out, page-15

Ha speeding ticket, no mention of current roadshows.
Gave a little bit of info but not much...6 weeks until trials end.

5. CBio is aware of two research reports recently completed by institutional stockbroking firm Lodge Partners Ltd and research firm Wise-Owl. Both reports highlight the potential impact of the current Phase IIa trial that are due to finish dosing in approximately 6 weeks (late March 2011) and the potential size of a
collaboration/licensing agreement with a major pharmaceutical company that could be negotiated post this trial.

The Wise-Owl report dated the 20 th February give a valuation of $1.47 and the Lodge report dated the 19 th January gives a valuation of $0.82 per share.

Both these reports can be found on our company website under the ?Investor Relations? tab. The ASX refused
to allow these reports, which the Company considers to be price sensitive, to be released on the ASX
platform.